Table 1: Characteristic Patients.
| Median (range) Age, y | 73.5 (62-77) |
| ANC × 103/uL (range) | 2.9 (2.8-3.3) |
| Hgb g/dL (range) | 12 (9.3-12.6) |
| Platelet × 103/uL (range) | 124 (59-225) |
| CLCr ml/min (range) | Not required |
|
Comorbidity • Diabetes Mellitus • Hypertension controlled by medication • Atrial Fibrillation or other cardiac arrhythmias • Chronic obstructive bronchopneumonia • Reversible ischemic attacks • Vascular cerebropathy |
yes yes yes yes yes yes |
| Median number of prior therapies | 1 (1-2) |
| Median number of lenalidomide cycles | 12 (6-19 cycles) |
|
ORR with previous treatments (n. patients) • PR • VGPR • CR |
4 3 1 0 |
|
ORR with "lenalidomide + dexamethasone" (n. patients) • PR • VGPR • CR |
4 2 1 1 |
| Median duration of response, months (range) | 13.5 (6-21) |
|
Non-Hematological Toxicities (grade ≥ 3) • Diarrhea • Constipation • Thromboembolic events • Infections |
0 0 0 0 0 |
|
Hematological Toxicities (grade ≥ 3) • Neutropenia • Thrombocytopenia |
0 1 |
ANC: Absolute Neutrophil Count; Hgb: Hemoglobin; CLCr: Creatinine Clearance.